Moore Kuehn Encourages AMNB, SCU, NLTX, and PRDS Investors to Contact Law Firm NEW YORK, July 26, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...

ImCheck Provides Promising Updated Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at SITC Meeting 2021 Oral presentation includes positive safety data across a wide range of ICT01 doses and efficacy data from patients receiving ICT01 plus pembrolizumab confirming durable clinical responses at low ICT01...

Neoleukin Therapeutics and Aquinox Pharmaceuticals Complete Merger Transaction Nasdaq Ticker Symbol “NLTX” to be effective Monday, August 12, 2019 SEATTLE, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”), a biopharmaceutical company...

Aquinox Pharmaceuticals and Neoleukin Therapeutics announce merger agreement • Combined company capitalized with approximately $65M to develop novel immunotherapies • Sophisticated computational platform enables new class of de novo protein therapeutics • Lead program,...